January 2016, Vol. 3, No. 1 - Letter to Our Readers
Dear Colleague, I hope you had great holidays and a happy New Year! In this first issue of the year, we feature an in-depth review about immune checkpoint inhibition in patients with colorectal cancer. This is a continuation of our series on immunotherapy in specific disease states. In this article, [ Read More ]
November 2015, Vol. 2, No. 6 - Letter to Our Readers
Dear Colleague, We are pleased to continue our in-depth coverage of the role of immunotherapy in oncology care. Immunotherapy has long captured the interest of researchers combating disease, and none more so than oncology researchers. Recent advances in immunotherapy have made headlines and been the main attraction at association meetings. [ Read More ]
September 2015, Vol. 2, No. 5 - Letter to Our Readers
Dear Colleague, I am writing to you with a renewed enthusiasm for the field of immunotherapy in oncology after hosting the World Cutaneous Malignancies Congress this summer! This educational opportunity is an event of which I am proud, as world-renowned experts convene to present the most up-to-date information on the [ Read More ]
July 2015, Vol. 2, No. 4 - Uncategorized
Surgery may not be appropriate in advanced basal cell carcinoma (BCC), such as those in difficult-to-treat locations or when the deformity would be substantial. At the Third Annual World Cutaneous Malignancies Congress, a panel discussed a complex case of advanced BCC, offering their opinions on the need for imaging, surgery, [ Read More ]
May 2015, Vol. 2, No. 3 - Letter to Our Readers
Dear Colleague, In this issue of Immunotherapy in Oncology (ITO), we continue to explore the many facets of immunotherapy, reaching beyond the basic science to bring you the practical implications of its usefulness. We are pleased to report that the FDA recently approved nivolumab injection, for intravenous use, for the [ Read More ]
March 2015, Vol. 2, No. 2 - Letter to Our Readers
Dear Colleague, In the new era of personalized treatment for patients battling cancer, the topic of immunotherapy is front and center in our discussions. The possibility of harnessing the power of our own immune system to combat cancer has captivated the imagination of researchers, clinicians, and the public alike. The [ Read More ]
January 2015, Vol. 2, No. 1 - Letter to Our Readers
Dear Colleague, Welcome to the 2015 series of Immunotherapy in Oncology (ITO)! In recognition of the enormous advances being made in immuno-oncology and the overwhelming reception by our readership to this journal, the publishers of ITO and I are delighted to announce an increased issuance of this timely and essential [ Read More ]
November 2014, Part 4 - Letter to Our Readers
Dear Colleague, Immunotherapy is a term we have heard for years, if not decades, but the fruits of researchers’ labor have just recently begun to be realized, most notably in the field of melanoma. As a result, so many of us associate immunotherapy with melanoma. True, we have seen great [ Read More ]
October 2014, Vol 3, No 7 - Letter to Our Readers
Dear Colleague, Personalized Medicine in Oncology (PMO) is pleased to present the third annual meetings of both the World Cutaneous Malignancies Congress (WCMC) and PMO Live: A Global Biomarkers Consortium Initiative. These will take place consecutively in San Francisco, California, October 29 – November 1, 2014. As Coeditor in Chief [ Read More ]
June 2014, Vol 3, No 4 - Letter to Our Readers
To Our Reading Community, It gives me great pleasure to present this issue of Personalized Medicine in Oncology (PMO). We constantly and thoroughly examine every aspect of our journal – appearance, readability, and, most importantly, editorial content. With input from our expert editorial board and our readership, we are always [ Read More ]
April 2014, Part 1 - Uncategorized
Dear Colleague, Personalized Medicine in Oncology (PMO) is proud to present a 4-part supplement series to our reading community focused on the timely issue of immunotherapy and its role in personalizing cancer care. Harnessing the power of the immune system to combat cancer is not a new idea; however, the [ Read More ]
August 2013, Vol 2, No 5 - Uncategorized
Key Points Introduction of multiple VEGFR TKIs with slightly different inhibition profiles lends itself to increasingly personalized treatments Tumor heterogeneity may complicate this approach Multiple biopsies may better determine the overall mutational burden of an RCC tumor, but this strategy is hampered by practical limitations and cost of technology We [ Read More ]
June 2013, Vol 2, No 4 - Uncategorized
Dear Colleague, Angelina Jolie’s recent surgery might be termed “the double mastectomy heard ’round the world.” It certainly holds important lessons for physicians, the public, and for your product’s market access. Ms Jolie’s treatment decision, a response to the dreaded mutation of the BRCA gene that gave her a 90% [ Read More ]
December 2012, Vol 1, No 6 - Melanoma
The incidence of melanoma in the United States is increasing at an alarming rate (Figure 1).1 In men, melanoma is increasing more rapidly than in any other cancer; in women, it is increasing more rapidly than any other cancer except lung cancer.2 In 2012, an estimated 76,250 new cases of [ Read More ]
Copyright 2023. Amplity Medical Communications. All Rights Reserved. Privacy Policy. Sitemap.
